Business, energy, technology, markets and global industry news from Business News Today

Novo Nordisk

PharmaDeviceNews Novo Nordisk
Pharma & Biotech

What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization

Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.

Read More
Representative image of a laboratory Alzheimer’s biomarker study, highlighting plasma tau testing and cognitive decline analysis, as C2N Diagnostics advances its PrecivityTauDx programme with Phase 3 evidence for tangle biomarkers.
Medical Devices & Diagnostics

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.

Read More
Pharma & Biotech

Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy

Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.

Read More
Pharma & Biotech

Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?

Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.

Read More
Novo Nordisk’s higher-dose Wegovy nears EU launch with 20.7% weight loss
Pharma & Biotech

Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?

Novo Nordisk's semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.

Read More
Novo Nordisk closes $5.2bn acquisition of Akero Therapeutics and its MASH pipeline.
Pharma & Biotech

Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care

Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.

Read More
Novo Nordisk is seeking approval for 7.2 mg Wegovy (semaglutide) from the FDA .
Pharma & Biotech

Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?

Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.

Read More